Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:IBRX NASDAQ:KYMR NASDAQ:PHVS NYSE:QGEN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeIBRXImmunityBio$7.76-7.4%$8.00$1.91▼$12.43$8.78B0.0213.24 million shs18.75 million shsKYMRKymera Therapeutics$84.63-1.9%$84.25$28.06▼$103.00$7.10B2.06507,363 shs637,460 shsPHVSPharvaris$29.68-1.4%$27.75$14.59▼$31.14$1.97B-2.34317,099 shs213,772 shsQGENQiagen$33.50-2.7%$40.93$33.17▼$57.81$7.10B0.642.06 million shs3.13 million shsThe 7 Hottest IPOs On Wall Street’s 2026 WatchlistMarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceIBRXImmunityBio-7.40%+9.30%+13.12%+28.26%+310.58%KYMRKymera Therapeutics-1.89%+4.39%-0.55%+6.33%+190.72%PHVSPharvaris-1.43%-4.29%+6.61%+12.34%+73.57%QGENQiagen-2.77%-3.12%-16.50%-34.42%-25.19%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeIBRXImmunityBio$7.76-7.4%$8.00$1.91▼$12.43$8.78B0.0213.24 million shs18.75 million shsKYMRKymera Therapeutics$84.63-1.9%$84.25$28.06▼$103.00$7.10B2.06507,363 shs637,460 shsPHVSPharvaris$29.68-1.4%$27.75$14.59▼$31.14$1.97B-2.34317,099 shs213,772 shsQGENQiagen$33.50-2.7%$40.93$33.17▼$57.81$7.10B0.642.06 million shs3.13 million shsThe 7 Hottest IPOs On Wall Street’s 2026 WatchlistMarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceIBRXImmunityBio-7.40%+9.30%+13.12%+28.26%+310.58%KYMRKymera Therapeutics-1.89%+4.39%-0.55%+6.33%+190.72%PHVSPharvaris-1.43%-4.29%+6.61%+12.34%+73.57%QGENQiagen-2.77%-3.12%-16.50%-34.42%-25.19%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceIBRXImmunityBio 2.86Moderate Buy$14.4085.57% UpsideKYMRKymera Therapeutics 2.96Moderate Buy$118.1039.54% UpsidePHVSPharvaris 2.71Moderate Buy$42.7343.96% UpsideQGENQiagen 2.50Moderate Buy$46.3838.44% UpsideCurrent Analyst Ratings BreakdownLatest PHVS, IBRX, QGEN, and KYMR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/7/2026QGENQiagen TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold$46.00 ➝ $40.005/6/2026KYMRKymera Therapeutics Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$106.005/5/2026IBRXImmunityBio D. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$23.004/30/2026KYMRKymera Therapeutics Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight$119.004/30/2026QGENQiagen Deutsche Bank AktiengesellschaftSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$43.004/29/2026QGENQiagen BarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetEqual Weight$44.00 ➝ $38.004/29/2026QGENQiagen Robert W. BairdSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetNeutral ➝ Outperform$53.00 ➝ $43.004/29/2026QGENQiagen Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold4/29/2026QGENQiagen Robert W. BairdSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Strong-Buy$43.004/29/2026QGENQiagen JPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$60.00 ➝ $45.004/29/2026QGENQiagen CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetNeutral$55.00 ➝ $38.00(Data available from 5/8/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookIBRXImmunityBio$113.29M71.74N/AN/A($0.51) per share-15.22KYMRKymera Therapeutics$39.21M177.55N/AN/A$18.72 per share4.52PHVSPharvarisN/AN/AN/AN/A$4.71 per shareN/AQGENQiagen$2.09B3.30$3.31 per share10.11$17.89 per share1.87Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateIBRXImmunityBio-$351.40M-$0.38N/AN/AN/A-310.18%N/A-81.40%5/11/2026 (Estimated)KYMRKymera Therapeutics-$311.35M-$3.57N/AN/AN/A-611.94%-24.71%-22.05%N/APHVSPharvaris-$198.79M-$3.37N/AN/AN/AN/A-70.96%-64.18%5/12/2026 (Estimated)QGENQiagen$424.88M$2.0217.5012.233.4219.16%14.09%8.26%N/ALatest PHVS, IBRX, QGEN, and KYMR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2026N/APHVSPharvaris-$0.8267N/AN/AN/AN/AN/A5/11/2026Q1 2026IBRXImmunityBio-$0.08-$0.62-$0.54-$0.62$43.07 million$44.21 million5/7/2026Q1 2026QGENQiagen$0.54$0.54N/A$0.33$496.15 million$492.32 million4/30/2026Q1 2026KYMRKymera Therapeutics-$0.89-$0.71+$0.18-$0.71$8.27 million$34.37 million4/3/2026Q4 2025PHVSPharvaris-$0.69-$0.84-$0.15-$0.84N/AN/A2/26/2026Q4 2025KYMRKymera Therapeutics-$0.77-$0.97-$0.20-$0.97$14.80 million$2.87 million2/23/2026Q4 2025IBRXImmunityBio-$0.08-$0.06+$0.02-$0.06N/A$38.29 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthIBRXImmunityBioN/AN/AN/AN/AN/AKYMRKymera TherapeuticsN/AN/AN/AN/AN/APHVSPharvarisN/AN/AN/AN/AN/AQGENQiagen$0.260.78%N/A12.87%N/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioIBRXImmunityBioN/A5.105.08KYMRKymera TherapeuticsN/A10.8110.81PHVSPharvarisN/A10.1110.11QGENQiagen0.443.903.31Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipIBRXImmunityBio8.58%KYMRKymera TherapeuticsN/APHVSPharvarisN/AQGENQiagen70.00%Insider OwnershipCompanyInsider OwnershipIBRXImmunityBio69.48%KYMRKymera Therapeutics16.01%PHVSPharvaris11.84%QGENQiagen9.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableIBRXImmunityBio5901.05 billion319.65 millionOptionableKYMRKymera Therapeutics17082.26 million69.09 millionOptionablePHVSPharvaris3065.41 million57.66 millionNot OptionableQGENQiagen5,654206.07 million187.53 millionOptionablePHVS, IBRX, QGEN, and KYMR HeadlinesRecent News About These CompaniesQiagen Files U.S. GAAP Quarterly Report for First Quarter 20261 hour ago | tipranks.comQIAGEN Plans to Launch New Fully Automated Sample to Insight Workflow and an AI-Enabled Risk Stratification Tool to Advance QuantiFERON Latent TB TestingMay 7 at 10:22 AM | finance.yahoo.comQGEN SHAREHOLDER INVESTIGATION: Levi & Korsinsky Investigates Qiagen for Possible Securities Law ViolationsMay 7 at 9:00 AM | globenewswire.comQiagen: Q1 Earnings SnapshotMay 6 at 11:51 PM | stamfordadvocate.comSQiagen (QGEN) Q1 Earnings and Revenues Lag EstimatesMay 6 at 10:51 PM | zacks.comQiagen (QGEN) Q1 Earnings: Taking a Look at Key Metrics Versus EstimatesMay 6 at 10:30 PM | zacks.comLevi & Korsinsky Investigates Qiagen N.V. (QGEN) Over Potential Securities Fraud AllegationsMay 6 at 7:20 PM | newsfilecorp.comNQGEN Investors Have Opportunity to Join Qiagen N.V. Fraud Investigation with the Schall Law FirmMay 6 at 6:31 PM | globenewswire.comQIAGEN Reports Full Results for Q1 2026May 6 at 4:05 PM | businesswire.comQiagen Investigation Initiated: Levi & Korsinsky Investigates the Officers and Directors of Qiagen N.V. (QGEN)May 6 at 9:00 AM | prnewswire.comVanguard Group Inc. Purchases 118,135 Shares of Qiagen N.V. $QGENMay 6 at 8:14 AM | marketbeat.comQiagen (QGEN) Gets a Buy from DZ BANK AGMay 5 at 10:47 PM | theglobeandmail.comBrokerages Set Qiagen N.V. (NYSE:QGEN) PT at $53.64May 4, 2026 | americanbankingnews.comQiagen Cuts 2026 Outlook as QuantiFERON Immigration Testing Slumps Despite EPS MatchMay 3, 2026 | marketbeat.comQiagen (NYSE:QGEN) Upgraded at Zacks ResearchMay 2, 2026 | americanbankingnews.comHow The Qiagen (QGEN) Investment Story Is Shifting As Analysts Rework Their AssumptionsMay 1, 2026 | finance.yahoo.comQiagen (NYSE:QGEN) Upgraded by Zacks Research to "Hold" RatingMay 1, 2026 | marketbeat.comOngoing Investigation into Qiagen N.V. (QGEN): Contact Levi & Korsinsky About Potential FraudApril 30, 2026 | newsfilecorp.comNQiagen (NYSE:QGEN) Price Target Lowered to $45.00 at JPMorgan Chase & Co.April 30, 2026 | americanbankingnews.comQiagen Sets Date for Publication of 2025 Annual Financial ReportApril 30, 2026 | theglobeandmail.comBaird upgrades Qiagen NV (QGEN)April 30, 2026 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimePHVS, IBRX, QGEN, and KYMR Company DescriptionsImmunityBio NASDAQ:IBRX$7.76 -0.62 (-7.40%) Closing price 05/7/2026 04:00 PM EasternExtended Trading$7.82 +0.06 (+0.72%) As of 07:56 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.ImmunityBio, Inc., a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies. The company's platforms have generated therapeutic agents that are currently being or planned to be studied in clinical trials across various indications in liquid and solid tumors, including bladder, lung and colorectal cancers, and glioblastoma multiforme. Its lead biologic product candidate is Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors. The company has collaboration agreements with National Cancer Institute. It also has license agreements with 3M Innovative Properties Company; Access to Advanced Health Institute; LadRx Corporation; Sanford Health; Shenzhen Beike Biotechnology Co. Ltd.; Viracta Therapeutics, Inc.; and GlobeImmune, Inc. The company is based in San Diego, California.Kymera Therapeutics NASDAQ:KYMR$84.63 -1.63 (-1.89%) Closing price 05/7/2026 04:00 PM EasternExtended Trading$84.70 +0.07 (+0.08%) As of 07:54 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company develops STAT6, a Type 2 inflammation in allergic diseases; and TYK2, a treatment for inflammatory bowel disease, psoriasis, psoriatic arthritis, and lupus. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.Pharvaris NASDAQ:PHVS$29.68 -0.43 (-1.43%) Closing price 05/7/2026 04:00 PM EasternExtended Trading$32.20 +2.52 (+8.50%) As of 07:52 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial. The company operates in the Netherlands, Switzerland, and the United States. Pharvaris N.V. was incorporated in 2015 and is based in Leiden, the Netherlands.Qiagen NYSE:QGEN$33.50 -0.94 (-2.73%) Closing price 05/7/2026 03:59 PM EasternExtended Trading$33.53 +0.03 (+0.10%) As of 07:46 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials. The firm assay technologies make these biomolecules visible and ready for analysis. Its bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. The company was founded by Detlev H. Riesner and Metin Colpan on April 29, 1996, and is headquartered in Venlo, the Netherlands. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas The AI Fear Around Datadog Stock May Have Been Completely Wrong Amprius Technologies Ups the Voltage on Forward Outlook Why Lam Research Still Looks Like a Buy After a 300% Rally IonQ Just Posted a Breakout Quarter—But 1 Problem Remains Super Micro Surges Over 20% as Margins Soar, Sales Fall Short Nuts and Bolts AI Play Gains Momentum: Astera Labs Targets Raised Anheuser-Busch Stock Jumps as Volume Growth Signals Turnaround Light Speed Returns: Corning Cashes In on NVIDIA Growth Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
